CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cantabio Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cantabio Pharmaceuticals Inc
2225 E Bayshore Rd Ste 200
Phone: (302) 645-7400p:302 645-7400 PALO ALTO, CA  94303-3220  United States Ticker: CTBODCTBOD

This company ceased filing statements with the SEC on 6/21/2019.

Business Summary
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focusing on commercializing therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Its strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into a drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the Company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
-Yes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20183/31/2018YesYes---

Industries
SIC Code Description
8741 Management services
8742 Management consulting services

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer GergelyToth 5/22/2015 5/22/2015
Chief Operating Officer Thomas R.Sawyer 5/22/2015 5/22/2015
Director MaxZhu 36 10/12/2018 10/12/2018

Business Names
Business Name
Cantabio Acquisition Inc.
CTBO
CTBOD
Gardedam Therapeutics, Inc.

General Information
Number of Employees: 3 (As of 3/31/2014)
Outstanding Shares: 22,549 (As of 6/20/2019)
Shareholders: 25
Stock Exchange: OTC
Federal Tax Id: 990373067
Fax Number: (302) 636-5454


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, July 17, 2019